Business Context and Reporting Period
This Form 8-K Current Report was filed by Aldeyra Therapeutics, Inc. on July 27, 2018, with the earliest event reported on that date. The filing addresses Item 5.02 regarding the departure of a former officer and the appointment of a new Chief Financial Officer (CFO).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and separation terms.
- New CFO Base Salary: $370,008 per year.
- New CFO Target Bonus: 35% of base salary.
- New CFO Equity Grant: 75,000 nonstatutory stock options vesting over four years.
- New CFO Relocation Reimbursement: Up to $80,000 (net of taxes).
- Former CFO Separation Lump Sum: $124,704.
Material Changes
The primary material change is the leadership transition in the finance function effective July 27, 2018:
- Departure: Stephen Tulipano ceased serving as CFO. His separation is treated as a termination without "cause."
- Appointment: Joshua Reed was appointed as CFO and principal financial and accounting officer effective July 30, 2018.
- Consulting Arrangement: Mr. Tulipano entered a consulting agreement for at least 12 months to facilitate the continued vesting of his outstanding stock options.
Outlook, Risks, and Contingencies
The filing details specific severance contingencies for both executives:
- Mr. Reed Severance: In the event of termination without cause or resignation for good reason, he is entitled to 9 months of base salary, a lump-sum bonus payment (greater of target or actual), and 9 months of COBRA premiums.
- Mr. Tulipano Severance: He received 9 months of continued base salary, a lump-sum payment of $124,704, and 9 months of COBRA premiums.
- Documentation: Full text of the offer letter, separation letter, and consulting agreement will be filed as exhibits to the Form 10-Q for the period ending September 30, 2018.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 75,000 stock options granted to Joshua Reed in the upcoming Form 10-Q.
- Confirm the total cash compensation impact of Mr. Tulipano's separation package and consulting agreement.
- Review the full text of the separation and consulting agreements to understand any non-compete or confidentiality restrictions.
- Monitor the upcoming Form 10-Q for the formal filing of the offer letter and separation documents referenced in this 8-K.